BCRX
BioCryst Pharmaceuticals, Inc.
9.68
1 x 8.31
1 x 11.18
bid
ask
+
0.03
0.26%
10:18 AM
timesize
| Ytd | 24.04% | |
| 1y | 7.26% |
9.58
day range
9.83
6.00
52 week range
10.94
| Open | 9.74 | Prev Close | 9.65 | Low | 9.58 | High | 9.83 | Mkt Cap | 2.46B |
| Vol | 372.35K | Avg Vol | 4.95M | EPS | -1.77 | P/E | N/A | Forward P/E | 14.19 |
| Beta | 0.56 | Short Ratio | 10.68 | Inst. Own | 101.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 8.94 | 200-d Avg | 8.00 | 1yr Est | 21.30 |
| Income Statement | |||
| Total Revenue | 156.41M | ||
| Revenues (USD) | 156.41M | ||
| Cost of Revenue | 5.38M | ||
| Gross Profit | 151.04M | ||
| Operating Expenses | 852.63M | ||
| Research and Development Expense | 60.32M | ||
| Selling, General and Administrative Expense | 94.55M | ||
| Operating Income | -701.60M | ||
| Interest Expense | 19.78M | ||
| Income Tax Expense | 1.00M | ||
| Net Income | -721.81M | ||
| Net Income Common Stock | -721.81M | ||
| Net Income Common Stock (USD) | -721.81M | ||
| Consolidated Income | -721.81M | ||
| Earnings per Basic Share | -2.98 | ||
| Earnings per Basic Share (USD) | -2.98 | ||
| Earnings per Diluted Share | -2.98 | ||
| Earning Before Interest & Taxes (EBIT) | -701.03M | ||
| Earning Before Interest & Taxes (USD) | -701.03M | ||
| Weighted Average Shares | 242.26M | ||
| Weighted Average Shares Diluted | 242.26M | ||
| Balance Sheet | |||
| Cash and Equivalents | 172.45M | ||
| Cash and Equivalents (USD) | 172.45M | ||
| Investments | 87.38M | ||
| Investments Current | 66.81M | ||
| Investments Non-Current | 20.57M | ||
| Trade and Non-Trade Receivables | 109.27M | ||
| Current Assets | 373.63M | ||
| Property, Plant & Equipment Net | 22.99M | ||
| Total Assets | 465.05M | ||
| Debt Current | 43.41M | ||
| Total Debt | 858.08M | ||
| Current Liabilities | 195.39M | ||
| Debt Non-Current | 814.67M | ||
| Total Liabilities | 1.02B | ||
| Accumulated Retained Earnings (Deficit) | -2.23B | ||
| Accumulated Other Comprehensive Income | -368.00K | ||
| Shareholders Equity | -553.84M | ||
| Shareholders Equity (USD) | -553.84M | ||
| Assets Non-Current | 91.43M | ||
| Total Debt (USD) | 858.08M | ||
| Deferred Revenue | 14.24M | ||
| Inventory | 34.16M | ||
| Liabilities Non-Current | 823.50M | ||
| Trade and Non-Trade Payables | 10.96M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 461.00K | ||
| Net Cash Flow from Financing | 412.55M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 82.04M | ||
| Capital Expenditure | -403.00K | ||
| Net Cash Flow - Business Acquisitions and Disposals | -489.48M | ||
| Issuance (Purchase) of Equity Shares | 19.48M | ||
| Issuance (Repayment) of Debt Securities | 394.23M | ||
| Net Cash Flow from Investing | -268.65M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 221.24M | ||
| Net Cash Flow from Operations | -61.79M | ||
| Effect of Exchange Rate Changes on Cash | -72.00K | ||
| Share Based Compensation | 16.03M | ||